Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 12—December 2003
Dispatch

Visceral Leishmaniasis Treatment, Italy

Luigi Gradoni*Comments to Author , Marina Gramiccia*, and Aldo Scalone*
Author affiliations: *Istituto Superiore di Sanità, Rome, Italy

Main Article

Table

First-line drugs used for treatment of visceral leishmaniasis in 533 immunocompetent patients in Italy and drug treatment failures recordeda

Y MA (%) L-AmB ABCD ABLC dAmB Any AmB drugs (%)
1995
57 (55.9)
3 R
45
1 R
0
0
0
45 (44.1)
1 R
1996
35 (50.0)
2 R
35
1 R
0
0
0
35 (50.0)
1 R
1997
26 (39.4)
3 U, 1 R
34
2 R
5
0
1
40 (60.6)
2 R
1998
14 (28.0)
1 R
32
1 R
4
0
0
36 (72.0)
1 R
1999
13 (21.0)
1 U, 1 R
45
2 R
2
1
1
49 (79.0)
2 R
2000
11 (9.8)
1 U, 3 R
89
1 U, 1 R
10
1 U
1
1 R
1
101 (90.2)
2 U, 2 R
2001
2 (2.8)
68
1 R
0
1
0
69 (97.2)
1 R
Total 158 (29.6) 5 U, 11 R 348
1 U, 9 R 21
1 U 3
1 R 3 375 (70.4)
2 U, 10 R

aMA, meglumine antimoniate; L-AmB, liposomal amphotericin B; ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; dAmB, amphotericin B desoxycholate; U, unresponsiveness and/or acute toxicity; R, relapse.

Main Article

Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external